158 related articles for article (PubMed ID: 2243347)
1. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.
Boughattas NA; Lévi F; Fournier C; Hecquet B; Lemaigre G; Roulon A; Mathé G; Reinberg A
J Pharmacol Exp Ther; 1990 Nov; 255(2):672-9. PubMed ID: 2243347
[TBL] [Abstract][Full Text] [Related]
2. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice.
Boughattas NA; Lévi F; Fournier C; Lemaigre G; Roulon A; Hecquet B; Mathé G; Reinberg A
Cancer Res; 1989 Jun; 49(12):3362-8. PubMed ID: 2720689
[TBL] [Abstract][Full Text] [Related]
3. Circadian variation of 5-fluorouracil and cis-platinum toxicity in mice.
Shakil A; Hirabayashi N; Toge T
Hiroshima J Med Sci; 1993 Dec; 42(4):147-54. PubMed ID: 8014066
[TBL] [Abstract][Full Text] [Related]
4. Circadian time dependence of murine tolerance for carboplatin.
Boughattas NA; Lévi F; Hecquet B; Lemaigre G; Roulon A; Fournier C; Reinberg A
Toxicol Appl Pharmacol; 1988 Nov; 96(2):233-47. PubMed ID: 3057682
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice.
Li XM; Metzger G; Filipski E; Boughattas N; Lemaigre G; Hecquet B; Filipski J; Levi F
Toxicol Appl Pharmacol; 1997 Apr; 143(2):281-90. PubMed ID: 9144445
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel chronopharmacology in mice.
Tampellini M; Filipski E; Liu XH; Lemaigre G; Li XM; Vrignaud P; François E; Bissery MC; Lévi F
Cancer Res; 1998 Sep; 58(17):3896-904. PubMed ID: 9731500
[TBL] [Abstract][Full Text] [Related]
8. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
9. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
10. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
Ohno S; Strebel FR; Stephens LC; Siddik ZH; Makino M; Klostergaard J; Tomasovic SP; Khokhar AR; Bull JM
Cancer Res; 1992 Aug; 52(15):4096-101. PubMed ID: 1638521
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.
Prajda N; Kralovánszky J; Gal F; Kiss F; Kerpel-Fronius S
In Vivo; 1989; 3(4):267-70. PubMed ID: 2519864
[TBL] [Abstract][Full Text] [Related]
12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
13. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice.
Filipski E; Amat S; Lemaigre G; Vincenti M; Breillout F; Lévi FA
J Pharmacol Exp Ther; 1999 Apr; 289(1):231-5. PubMed ID: 10087009
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
15. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
16. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Thomas JP; Lautermann J; Liedert B; Seiler F; Thomale J
Mol Pharmacol; 2006 Jul; 70(1):23-9. PubMed ID: 16569706
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line.
Asada N; Tsuchiya H; Ueda Y; Tomita K
Anticancer Res; 1998; 18(3A):1765-8. PubMed ID: 9673402
[TBL] [Abstract][Full Text] [Related]
18. Circadian-time dependent tolerance and haematological toxicity to isoniazid in murine.
Souayed N; Chennoufi M; Boughattas F; Hassine M; Ben Attia M; Aouam K; Reinberg A; Boughattas NA
Biomed Pharmacother; 2015 Apr; 71():233-9. PubMed ID: 25960242
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cisplatin chronotoxicity related to reduced glutathione in mice.
Boughattas NA; Li XM; Filipski J; Lemaigre G; Filipski E; Bouzouita K; Belhadj O; Lévi F
Hum Exp Toxicol; 1996 Jul; 15(7):563-72. PubMed ID: 8818709
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic analysis of platinum in the continuous CDDP-CBDCA treatment; its relation to the changes of blood biochemistry].
Chen JT; Hasumi K
Gan To Kagaku Ryoho; 1995 Apr; 22(5):653-7. PubMed ID: 7717717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]